Customize your JAMA Network experience by selecting one or more topics from the list below.
Worsham MJ, Chen KM, Tiwari N, et al. Fine-Mapping Loss of Gene Architecture at the CDKN2B (p15INK4b), CDKN2A (p14ARF, p16INK4a), and MTAP Genes in Head and Neck Squamous Cell Carcinoma. Arch Otolaryngol Head Neck Surg. 2006;132(4):409–415. doi:10.1001/archotol.132.4.409
To identify the extent and the smallest region of loss for CDKN2BINK4b, CDKN2AARF,INK4a, and MTAP. Homozygous deletions of human chromosome 9p21 occur frequently in malignant cell lines and are common in squamous cell carcinoma of the head and neck (HNSCC). This complex region encodes the tumor suppressor genes cyclin-dependent kinase 2B (CDKN2B) (p15INK4b) and CDKN2A (p14ARF, p16INK4a) and the housekeeping gene methylthioadenosine phosphorylase (MTAP).
A targeted probe panel designed to finely map the region of 9p21 loss comprised 3 probes for CDKN2BINK4b, 7 for CDKN2AARF, INK4a, and 3 for MTAP and was interrogated using the multiplex ligation-dependent probe amplification assay (MLPA). The MLPA genomic copy number alterations for CDKN2A were validated using real-time polymerase chain reaction.
Six HNSCC primary (A) and recurrent or metastatic (B) cell lines were examined: UMSCC-11A/11B, UMSCC-17A/17B, and UMSCC-81A/81B.
Cell line UMSCC-11B retained all 9p loci tested in the region. Cell lines UMSCC-17A/B indicated homozygous deletion of CDKN2AARF, INK4a starting at p16INK4 exon 1α to include exons 2 and 3. Homozygous loss was indicated for CDKN2BINK4b and CDKN2AARF,INK4a in UMSCC-11A, and UMSCC-81A. Cell line UMSCC-81B indicated retention of all 9p loci except for exon 1α (p16INK4a). Selective loss of the 3′ end of MTAP was observed in UMSCC-11A. Genomic alterations by fine-mapping MLPA were validated at the DNA level for CDKN2A.
We identified exon 1α (p16INK4a) as the smallest region of loss in the CDKN2AARF, INK4a gene. The frequency and precise loss of CDKN2BINK4b, CDKN2AARF, INK4a, and MTAP in the prognosis of 9p21-deleted HNSCC may provide impetus for use of these targets as therapeutic biomarkers in head and neck cancer.
Create a personal account or sign in to: